Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes

Pediatric Diabetes

Volumn 12, Issue 7, 2011, Pages 656-667

  Sumpter, Kathryn M ^a   Adhikari, Soumya ^a   Grishman, Ellen K ^a   White, Perrin C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CDNA microarray analysis; Gene expression; Immunomodulatory therapy

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LYMPHADENOPATHY; MALE; MICROARRAY ANALYSIS; MIXED MEAL TOLERANCE TEST; NEUTROPENIA; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SHORT COURSE THERAPY;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; C-PEPTIDE; CELLS, CULTURED; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GENE EXPRESSION PROFILING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS;

EID: 80055084799     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2011.00761.x     Document Type: Article

References (38)

1. Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 2010: 32: 488-499.
2. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC. Gene expression in peripheral blood mononuclear cells from children with diabetes. J Clin Endocrinol Metab 2007: 92: 3705-3711.
3. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010: 6: 158-166.
4. Bertera S, Alexander AM, Crawford ML et al. Gene combination transfer to block autoimmune damage in transplanted islets of Langerhans. Exp Diabesity Res 2004: 5: 201-210.
5. Giannoukakis N, Rudert WA, Ghivizzani SC et al. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999: 48: 1730-1736.
6. Tellez N, Montolio M, Biarnes M, Castano E, Soler J, Montanya E. Adenoviral overexpression of interleukin-1 receptor antagonist protein increases beta-cell replication in rat pancreatic islets. Gene Ther 2005: 12: 120-128.
7. Gysemans C, Stoffels K, Giulietti A et al. Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents. Diabetologia 2003: 46: 1115-1123.
8. Drage M, Zaccone P, Phillips JM et al. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice. Transplantation 2002: 74: 611-619.
9. Sandberg JO, Eizirik DL, Sandler S. IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 1997: 108: 314-317.
10. Sandberg JO, Eizirik DL, Sandler S, Tracey DE, Andersson A. Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival. Diabetes 1993: 42: 1845-1851.
11. Nicoletti F, Di Marco R, Barcellini W et al. Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 1994: 24: 1843-1847.
12. Sandberg JO, Andersson A, Eizirik DL, Sandler S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem Biophys Res Commun 1994: 202: 543-548.
13. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007: 356: 1517-1526.
14. Pickersgill LM, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial - background and rationale. Diabetes Metab Res Rev 2009: 25: 321-324.
15. National Institute of Diabetes and Digestive and Kidney Diseases. Canakinumab study in individuals with newly diagnosed type 1 diabetes (anti IL-1). 2009 (available from).
16. University of Texas Southwestern Medical Center. Rilonacept in diabetes mellitus type 1 (RID-1) 2009 (available from).
17. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J Immunol 2008: 180: 1929-1937.
18. Illumina Inc., San Diego, CA, 2010 (available from).
19. ARUP Laboratories. Method validation summary: insulin autoantibody, 2003.
20. ARUP Laboratories. Validation report: IA-2 antibody, 2003.
21. ARUP Laboratories. New instrument/assay validation worksheet: GAD antibody, 2009.
22. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003: 52: 1059-1065.
23. Mortensen HB, Hougaard P, Swift P et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009: 32: 1384-1390.
24. Calvano SE, Xiao W, Richards DR et al. A network-based analysis of systemic inflammation in humans. Nature 2005: 437: 1032-1037.
25. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009: 27: 519-550.
26. Gottlieb PA, Quinlan S, Krause-Steinrauf H et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010: 33: 826-832.
27. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009: 361: 2143-2152.
28. Allantaz F, Chaussabel D, Stichweh D et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007: 204: 2131-2144.
29. Sanda S, Bollyky J, Standifer N, Nepom G, Hamerman JA, Greenbaum C. Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. Clin Immunol 136: 170-173.
30. Palmer JP, Fleming GA, Greenbaum CJ et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004: 53: 250-264.
31. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989: 320: 550-554.
32. Knoell DL, Ralston DR, Coulter KR, Wewers MD. Alpha 1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-1beta, and tumor necrosis factor-alpha in monocytes. Am J Respir Crit Care Med 1998: 157: 246-255.
33. Kim KY, Kim HY, Kim JH et al. Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue. FEBS Lett 2006: 580: 3953-3960.
34. Bouchard C, Page J, Bedard A, Tremblay P, Vallieres L. G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions. Glia 2007: 55: 790-800.
35. Legrand-Poels S, Schoonbroodt S, Piette J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J 2000: 349: 765-773.
36. Forssmann U, Delgado MB, Uguccioni M, Loetscher P, Garotta G, Baggiolini M. CKbeta8, a novel CC chemokine that predominantly acts on monocytes. FEBS Lett 1997: 408: 211-216.
37. Toda Y, Tsukada J, Misago M, Kominato Y, Auron PE, Tanaka Y. Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. J Immunol 2002: 168: 1984-1991.
38. Rodenburg RJ, Brinkhuis RF, Peek R et al. Expression of macrophage-derived chemokine (MDC) mRNA in macrophages is enhanced by interleukin-1beta, tumor necrosis factor alpha, and lipopolysaccharide. J Leukoc Biol 1998: 63: 606-611.